Phase I study to evaluate of the gastric pH-dependent drug interaction between famitinib and the proton pump inhibitor omeprazole in healthy subjects [0.03%]
一项评价法米替尼与质子泵抑制剂奥美拉唑胃pH依赖性相互作用的I期临床研究
Linlin Hu,Mingmin Cai,Wei Qian et al.
Linlin Hu et al.
To evaluate the potential gastric pH-dependent drug-drug interaction (DDI), safety and tolerability of famitinib co-administered with omeprazole in healthy subjects. Twenty healthy subjects were enrolled in a single-center, single-arm, open...
CD25-targeted antibody-drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma [0.03%]
靶向CD25抗体药物偶联物卡美坦西辛治疗复发或难治性经典型霍奇金淋巴瘤
Bo Xu,Shaoqian Li,Bo Kang et al.
Bo Xu et al.
Classic Hodgkin lymphoma (cHL) accounts for more than 90% of HL in developed countries. Although the current combined modality therapy make it have a high cure rate, the prognosis for heavily pretreated patients with relapsed or refractory ...
Carbidopa suppresses estrogen receptor-positive breast cancer via AhR-mediated proteasomal degradation of ERα [0.03%]
卡比多巴通过AhR介导的ERα泛素蛋白酶体途径降解抑制雌激素受体阳性乳腺癌细胞生长
Zhiwei Chen,Xing Xia,Heyan Chen et al.
Zhiwei Chen et al.
Estrogen receptor-α (ERα) promotes breast cancer, and ER-positive cancer accounts for ~ 80% of breast cancers. This subtype responds positively to hormone/endocrine therapies involving either inhibition of estrogen synthesis or blockade o...
Comparison of dual mTORC1/2 inhibitor AZD8055 and mTORC1 inhibitor rapamycin on the metabolism of breast cancer cells using proton nuclear magnetic resonance spectroscopy metabolomics [0.03%]
基于氢核磁共振代谢组学的双靶点哺乳动物雷帕霉素靶蛋白信号通路抑制剂AZD8055与mTORC1抑制剂雷帕霉素对乳腺癌细胞代谢影响的比较研究
Zhitao Ni,Shaolin Xu,Zheng Yu et al.
Zhitao Ni et al.
Dual mTORC1/2 inhibitors may be more effective than mTORC1 inhibitor rapamycin. Nevertheless, their metabolic effects on breast cancer cells have not been reported. We compared the anti-proliferative capacity of rapamycin and a novel mTORC1...
Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2V617F and ASXL1 mutations [0.03%]
JAK2V617F和ASXL1双突变细胞中鲁索利替尼与ABT-737联合应用的协同效应研究
Jiajia Yuan,Junzhe Song,Chao Chen et al.
Jiajia Yuan et al.
The V617F mutation in Janus kinase 2 is considered one of the driver mutations leading to Philadelphia-negative myeloproliferative neoplasms (MPNs). Concurrent JAK2V617F and ASXL1 mutations accelerate the progression of myelofibrosis in pat...
BMP2 as a promising anticancer approach: functions and molecular mechanisms [0.03%]
有前景的抗肿瘤方法BMP2：功能及分子机制研究
Tong-Tong Li,Yong-Wei Lai,Xu Han et al.
Tong-Tong Li et al.
Bone morphogenetic protein 2 (BMP2), a pluripotent factor, is a member of the transforming growth factor-beta (TGF-β) superfamily and is implicated in embryonic development and postnatal homeostasis in tissues and organs. Experimental rese...
Correction to: Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine [0.03%]
Correction to: 黑素瘤肿瘤抗原和免疫亚型的分析以开发mRNA疫苗
Haiqin Ping,Wenjun Yu,Xiaoming Gong et al.
Haiqin Ping et al.
Published Erratum
Investigational new drugs. 2022 Dec;40(6):1356. DOI:10.1007/s10637-022-01296-6 2022
Two calix[4]pyrroles as potential therapeutics for castration-resistant prostate cancer [0.03%]
两种用于治疗去势抵抗性前列腺癌的潜在药物(calix[4]吡咯)
Imene Ben Toumia,Marco Ponassi,Paola Barboro et al.
Imene Ben Toumia et al.
Macrocyclic compounds meso-(p-acetamidophenyl)-calix[4]pyrrole and meso-(m-acetamidophenyl)-calix[4]pyrrole have previously been reported to exhibit cytotoxic properties towards lung cancer cells. Here, we report pre-clinical in vitro and i...
Correction to: A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: A case report [0.03%]
对NGS鉴定并经IHC和FISH验证的SLC8A1/LINC01913间质区-ALK融合突变致克唑替尼治疗IIB期肺腺癌患者未复发的病例报告的更正通知
Chunguang Wang,Shu Chen,Qianru He et al.
Chunguang Wang et al.
Published Erratum
Investigational new drugs. 2022 Dec;40(6):1357. DOI:10.1007/s10637-022-01292-w 2022
Neoadjuvant immunoradiotherapy in patients with locally advanced oral cavity squamous cell carcinoma: a retrospective study [0.03%]
局部晚期口腔鳞癌新辅助免疫放疗的回顾性研究
Peng Shen,Bo Qiao,Nenghao Jin et al.
Peng Shen et al.
Background: Although anti-programmed death receptor-1 (PD-1) agents have been evaluated in the neoadjuvant setting for the treatment of locally advanced head and neck cancer, including oral cavity squamous cell carcinoma ...